Sezer A et al. 1 Medical Oncology, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA 2 Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto/CA 3 Immunology, Campbell Family Institute for Cancer Research, University Health Network, M5G2M9M5G2M9 - Toronto/CA Dr. Marcus Butler Identify best practices when using immunotherapy for patient management. Search for more papers by this author. Dr. Marcus Butler, MD is an oncologist in Boston, Massachusetts. Active Member as of 10 Apr 2012 . Equivalent Induction of Telomerase-specific Cytotoxic T Lymphocytes from Tumor-bearing Patients and Healthy Individuals. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Marcus Butler, MD Clinical Head, Immune Monitoring Team Before joining The Princess Margaret Cancer Centre, Dr. Butler was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute. See Dr. Butler’s recent publications on PubMed or Google Scholar. Marcus Butler speaks exclusively to VJOncology, The Video Journal of Oncology. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. 2012 Feb 15, Marcus O. Butler, Osamu Imataki, Yoshihiro Yamashita, Makito Tanaka, Sascha Ansén, Alla Berezovskaya, Genita Metzler, Matthew I. Milstein, Mary M. Mooney, Andrew P. Mu...> ;PLOS ONE. Marcus Otho Butler . 2002 May 1, Robert H. Vonderheide, Joachim L. Schultze, Karen S. Anderson, B. Maecker, M. O. Butler, Z. Xia, M. J. Kuroda, M. von Bergwelt-Baildon, M. M. Bedor, K. M. Hoar, D. R. ...> ;Cancer Research. Symptoms of MBO are challenging to palliate and result in progressive decompensation of already vulnerable patients with limited therapeutic options and a short prognosis. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Nakatsugawa M, Rahman MA, Yamashita Y, …, Medical Oncology Fellowship, Dana-Farber/Partners CancerCare, Internal Medicine Residency, Johns Hopkins Hospital. Despite immune checkpoint inhibitor therapy becoming the standard of care across multiple tumor types, there are many unanswered questions that need to be addressed before this therapeutic modality can be fully harnessed. Dr. Marcus Butler, MD is a hematology specialist in Worcester, MA. Find your profile and take control of your online presence: Doximity / States / Massachusetts / Boston / Marcus Butler, MD, Dr. Marcus Butler, Dr. Marcus Butler, MD, Dr. M Butler, Dr. Marcus Otho Butler. He is licensed to practice by the state board in Massachusetts (81212). Restricted as of 10 Apr 2012 ... Division of Medical Oncology OPG 7-815 - 610 University Ave Toronto ON M5G 2M9 Phone: (416) 946-4501 Ext. He is the Clinical Head of the Immune Monitoring Team at The Princess Margaret Cancer Centre. 2006 May 15, Naoto Hirano, Marcus O. Butler, Zhinan Xia, Sascha Ansén, Michael von Bergwelt-Baildon, Donna Neuberg, Gordon J. Freeman, Lee M. Nadler> ;Blood. 2019 Feb 11, Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C., Saso, K., Butler, M. O., Minden, M. D., Hirano, N.> ;Nature medicine. iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries. Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers. 2018;379:341–351. 1996-12-01, NanoString Highlights the Results of Research Presented at the 2019 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), Warning Issued to Asthma and Hay Fever Sufferers over Fatal Attacks, From Dustbusters to a Soda Fix: 20 Health Hacks for Your Home, Detection Of Immunogenic Ovarian Cancer Antigens, A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma, Connect with other colleagues in the same hospital or clinic, Search all U.S. specialist profiles and refer a patient, Read the latest clinical news and earn CME/CEU credits. Brilliant, down to earth, patient centered. Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer Marcus Butler. Internal Medicine , Hematology/Oncology and Medical Oncology (617) 632-2173. Dr. Marcus O Butler, MD works in Boston, Massachusetts is a specialist in Oncology, Hematology and graduated Yale University School Of Medicine in 1992. Undergraduate Studies: University of South Carolina, Columbia, South Carolina. 2008 Feb 26, Marcus O. Butler, Jeng Shin Lee, Sascha Ansén, Donna Neuberg, F. Stephen Hodi, Andrew P. Murray, Linda Drury, Alla Berezovskaya, Richard C. Mulligan, Lee M. Nadler, Na...> ;Clinical Cancer Research. Co-leader, Immuno-oncology Translational Research Initiative (ACTION). His expertise includes clinical trials in a variety of immune therapies including adoptive T-cell therapy and checkpoint blockade. Medical Oncology/Cancer Clinical trials Unit, University Health Network, Toronto, ON Canada. Marcus.Butler@uhn.ca. 13University Health Network, Princess Margaret Cancer Centre, 9-622, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Background. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. 2011 Apr 27, Marcus O. Butler, Sascha Ansén, Makito Tanaka, Osamu Imataki, Alla Berezovskaya, Mary M. Mooney, Genita Metzler, Matthew I. Milstein, Lee M. Nadler, Naoto Hirano> ;International Immunology. Dr. Butler graduated from the Yale University School of Medicine in 1992. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Cancer Res.. 2001-11-01, Robert H. Vonderheide, Marcus O. Butler, Joyce F. Liu, Traci E. Battle, Naoto Hirano, John G. Gribben, David A. Frank, Joachim L. Schultze, Lee M. Nadler> ;International Journal of Oncology. University Health Network Researcher Page – Dr. Marcus Butler, Princess Margaret Cancer Centre – Tumor Immunotherapy Program Researchers, © 5485 The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. Malignant bowel obstruction (MBO) is a major complication in women with advanced gynecologic cancers which imposes a significant burden on patients, caregivers, and healthcare systems. This website uses cookies in order to optimize the user’s experience. All rights reserved. Le, Leila Khoja, Danny Ghazarian, Luisa Bonilla, Habeeb Majeed, David Hogg, Anthony M. Joshua, Michael Cru...> ;Cancer Immunology, Immunotherapy. 2012 Jan 12, Makito Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imataki, Alla Berezovskaya, Lee M. Nadler, Naoto Hirano> ;Clinical Cancer Research. Dr. Marcus O. Butler MD is a male hematology and oncology specialist in Boston, MA. Dana Farber Cancer Institute 44 Binney St Boston, MA 02115. September 19–21, 2020: LBA52. To learn more about how we use cookies on this website, please review our Website Privacy Statement (https://oicr.on.ca/website-privacy-statement). Before joining The Princess Margaret Cancer Centre, Dr. Butler was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute. Fellowship, Hematology/Oncology, 1996 - 2000, Residency, Internal Medicine, 1992 - 1995, Linh T. Nguyen, Samuel D. Saibil, Valentin Sotov, Michael X. According to first-in-human findings reported in a poster presentation during the ESMO Annual Congress, genetically engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4) appeared safe and demonstrated some evidence of antitumor activity. medRxiv - The Preprint Server for Health Sciences. University Health Network (UHN) is a research hospital affiliated with the University of Toronto and a member of the Toronto Academic Health Science Network. 2008 Oct 1, Zoltan Nagymanyoki, Marcus O. Butler, Michael J. Callahan, Mana M. Parast, Vilmos Fulop, Samuel C. Mok, Ross S. Berkowitz> ;Journal of Reproductive Medicine. 2005 Jan 1, Britta Maecker, David H. Sherr, Robert H. Vonderheide, Michael von Bergwelt-Baildon, Naoto Hirano, Karen S. Anderson, Zhinan Xia, Marcus O. Butler, Kai W. Wucherpfenni...> ;Blood. As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network. His expertise includes clinical trials in a variety of immune therapies including adoptive T-cell therapy and checkpoint blockade. Poster presented at European Society of Medical Oncology (ESMO) Virtual Congress 2020. Updated December 9, 2020.Figure 2 data corrected. Medical School: University of South Carolina School of Medicine, Columbia, South Carolina Marcus Butler, MD. N Engl J Med. Genet.. 1997-10-01, Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC, Dyomin V, Ohno H, Chaganti RS, Dalla-Favera R> ;Blood. Dr. Butler is affiliated with Brigham and Women's Hospital and practicing for 27 years Marcus Butler is a practicing Internal Medicine doctor in Boston, MA. Dr. Butler is the Clinical Head of the Immune Monitoring Team at the Princess Margaret Cancer Centre, where his group performs a wide variety of immunologic assays to examine the impact of therapies on immune phenotype and function. Dr. Marcus O Butler is a doctor primarily located in Boston, MA, with another office in Boston, MA. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic mela... CDR3β sequence motifs regulate autoreactivity of human invariant NKT cell receptors. 2011 Aug 15, Marcus O. Butler, Philip Friedlander, Matthew I. Milstein, Mary M. Mooney, Genita Metzler, Andrew P. Murray, Makito Tanaka, Alla Berezovskaya, Osamu Imataki, Linda Dru...> ;Science Translational Medicine. 2018 Feb 6, Guo, T., Ochi, T., Nakatsugawa, M., Kagoya, Y., Anczurowski, M., Wang, C., Rahman, M. A., Saso, K., Butler, M. O., Hirano, N.> ;Journal of visualized experiments : JoVE. | Accessibility | Policies. Surprising Things You Didn't Know About Dogs and Cats 9. 2021 Ontario Institute for Cancer Research. 2016 Nov 3, Khoja, L., Kibiro, M., Metser, U., Gedye, C., Hogg, D., Butler, M. O., Atenafu, E. G., Joshua, A. M.> ;British journal of cancer. He currently practices at Umass Memorial Children's Medical Center. 2006 Feb 15, Naoto Hirano, Marcus O. Butler, Eva C. Guinan, Lee M. Nadler, Seiji Kojima> ;British Journal of Haematology. Medical Oncology Site Group Lead: Marcus Butler Learn more about the inter-professional Melanoma & Skin Site Group and its specialized, innovative programs to assess, plan treatment and deliver care for cancer at all stages. Dr. Butler completed a residency at Johns Hopkins Med Center. Terms and Conditions | Website Privacy Statement The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. Marcus Otho Butler, MD is a hematology and oncology internal medicine in Boston, MA. Before joining the Princess Margaret Cancer Centre, he was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell al... Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Poster presented at ESMO Virtual Congress 2020. He has 29 years of experience. 2003 Apr 15, Michael von Bergwelt-Baildon, Robert H. Vonderheide, Britta Maecker, Naoto Hirano, Karen S. Anderson, Marcus O. Butler, Zhinan Xia, Wan Y. Zeng, Kai W. Wucherpfennig, ...> ;Blood. For opportunities to collaborate with Dr. Butler, please contact him directly. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. UPMC Hillman Cancer Center at Butler Health System offers state-of-the-art cancer care close to home.. Conveniently located on Oneida Valley Road, we specialize in medical oncology. Stratigos A et al. His fellow Luisa shows so much promise and is well on her way. 2008 Jul 1, F. Stephen Hodi, Marcus O. Butler, Darryl A. Oble, Michael V. Seiden, Frank G. Haluska, Andrea Kruse, Suzanne MacRae, Marybeth Nelson, Christine Canning, Israel Lowy, ...> ;Proceedings of the National Academy of Sciences of the United States of America. Instructor, Medicine, Brigham & Women's Hospital, Harvard Medical School. 2007 Mar 15, Naoto Hirano, Marcus O. Butler, Zhinan Xia, Alla Berezovskaya, Andrew P. Murray, Sascha Ansén, Lee M. Nadler> ;Clinical Cancer Research. Butler, Marcus Otho CPSO#: 97421 MEMBER STATUS. (best practices and/or cases from your practice using immunotherapy, focus on … Dr. Marcus Butler is the Clinical Co-Leader of OICR’s Immuno-oncology Translational Research Initiative. He is an advocate for patient rights, a clinical investigator and a teacher. This type of melanoma develops for unknown reasons unrelated to UV light exposure, … Funding provided by the Government of Ontario. Marcus Butler, MD. By continuing to use our website site without changing your browser settings, you consent to our use of cookies in accordance with, Immuno-oncology Translational Research Initiative, Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2, BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models, CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells, Specific roles of each TCR hemichain in generating functional chain-centric TCR, Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells, Medical Oncology Disease Site Lead for Melanoma/Skin Oncology, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Assistant Professor, Department of Medicine, University of Toronto, Associate Member, Department of Immunology, University of Toronto. September 19–21, 2020: LBA47. Presence of anti-kinectin and anti-PMS1 antibodies in japanese aplastic anaemia patients. Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in … His specialties include Internal Medicine, Hematology/Oncology, Medical Oncology. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8+ T cells, Ex vivo expansion of human CD8 + T cells using autologous CD4 + T cell help, Induction of HLA-DP4-restricted anti-Survivin Th1 and Th2 responses using an artificial antigen-presenting cell, Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells. Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain. He speaks English. 7. 2010 Nov 1, Sascha Ansén, Marcus O. Butler, Alla Berezovskaya, Andrew P. Murray, Kristen E. Stevenson, Lee M. Nadler, Naoto Hirano> ;Clinical Cancer Research. Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21, Antigen-Specific T Cell Immune Response Detected by Skewed T Cell Receptor Usage in Normal Placenta and Complete Molar Pregnancy, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell, Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses.